Sareum (LON:SAR) Trading 18.4% Higher – Time to Buy?

Sareum Holdings plc (LON:SAR) traded up 18.4% during trading on Wednesday . The stock traded as high as GBX 22 and last traded at GBX 21.90. 349,410 shares changed hands during mid-day trading, an increase of 47% from the average session volume of 237,019 shares. The stock had previously closed at GBX 18.50.

Sareum Trading Up 18.4%

The stock has a market cap of £30.24 million, a P/E ratio of -5.62 and a beta of -1.08. The company has a 50 day simple moving average of GBX 15.90 and a 200 day simple moving average of GBX 16.23.

Sareum (LON:SAR) last posted its quarterly earnings results on Thursday, March 12th. The company reported GBX (1.20) earnings per share for the quarter. As a group, sell-side analysts expect that Sareum Holdings plc will post -3.8 earnings per share for the current year.

Sareum Company Profile

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.